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QPCRa b s t r a c t
Widespread use of Pneumococcal Conjugate Vaccines (PCV) has reduced vaccine-type nasopharyngeal
colonisation and invasive pneumococcal disease. In a double-blind, randomised controlled trial using
the Experimental Human Pneumococcal Challenge (EHPC) model, PCV-13 (Prevenar-13) conferred 78%
protection against colonisation acquisition and reduced bacterial intensity (AUC) as measured by classical
culture. We used a multiplex qPCR assay targeting lytA and pneumococcal serotype 6A/B cpsA genes to re-
assess the colonisation status of the same volunteers. Increase in detection of low-density colonisation
resulted in reduced PCV efficacy against colonisation acquisition (29%), compared to classical culture
(83%). For experimentally colonised volunteers, PCV had a pronounced effect on decreasing colonisation
density. These results obtained in adults suggest that the success of PCV vaccination could primarily be
mediated by the control of colonisation density. Studies assessing the impact of pneumococcal vaccines
should allow for density measurements in their design.
 2019 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction pneumococcal diseases caused by vaccine-type serotypes in chil-Pneumonia is a leading cause of death in children under 5 years
worldwide, causing up to 1.4 million deaths annually [1]. Of these
deaths, approximately 38% are caused by Streptococcus pneumoniae
(pneumococcus) [2]. Current licensed pneumococcal conjugate
vaccines (PCVs) are highly effective in protecting against invasivedren [3]. Immunization with PCVs also has beneficial indirect
effects, conferring herd immunity to unvaccinated adults [4]. Dis-
ease and transmission prevention requires interruption of coloni-
sation [3]. Numerous studies have reported a reduction in
vaccine-type (VT) pneumococcal colonisation acquisition after
PCV vaccination, however, the impact of PCVs on pneumococcal
colonisation density is less clear [5–8]. Studies have shown that
vaccination with PCV reduces colonisation densities with VT sero-
types when comparing to control vaccines [5]. However, other
studies have reported that vaccination with PCV do not affect
pneumococcal density in children colonised by VT serotypes [7].
We have previously reported the results of a double-blind, ran-
domised controlled trial investigating the effect of the 13-valent
PCV (PCV-13, Prevnar-13, Pfizer) on pneumococcal colonisation
using the Experimental Human Pneumococcal Challenge (EHPC)
model [9]. PCV showed 78% protection against acquisition of pneu-
mococcus serotype 6B (BHN418) (5/48 became colonised in PCV
arm vs 23/48 in the control arm). Moreover, although the number
of volunteers who became experimentally colonised following PCV
vaccination was limited, we observed a significant reduction in
nasal pneumococcal colonisation density (3 log difference in PCV
arm compared to control arm at day 2) [9].
3954 E.L. German et al. / Vaccine 37 (2019) 3953–3956Interest in using molecular methods for colonisation detection
is increasing because of their high sensitivity and, therefore, their
ability to detect pneumococcus at low colonisation densities. Com-
bining the results of classical culture and molecular methods has
been suggested in order to improve accuracy of reported colonisa-
tion rates [10]. The lytA (autolysin) gene qPCR strategy developed
by the Centers for Disease Control (CDC) is currently the WHO-
recommended culture-independent method to detect pneumo-
cocci [11]. However, given the capacity of pneumococcus to
exchange genes with other streptococci [12] a multiplex approach
is valuable. Therefore, in this study, we employed a multiplex qPCR
assay targeting lytA and pneumococcal serotype 6A/B cpsA genes to
re-assess volunteer samples from our PCV study for experimental
colonisation of 6B pneumococcus. We compared the results
obtained by this molecular method with the results previously
obtained by classical culture.Table 1








PCV Control PCV Control
D2 2/38 (5) 18/39 (46) 11/38 (29) 21/39 (54)
D7 4/43 (9) 18/42 (43) 16/43 (37) 23/41 (56)
D14 1/9 (11) 18/23 (79) 2/9 (22) 17/23 (74)
Any Day 4/45 (9) 23/45 (51) 22/45 (49) 31/45 (69)
Risk Ratio (p-value) 0.17 (0.0005) 0.71 (0.06)
Definition of abbreviations: PCV = pneumococcal conjugate vaccine; NW = nasal
wash.2. Material and methods
2.1. PCV/EHPC clinical trial
A trial investigating the efficacy of the 13-valent PCV vaccine
against experimental human pneumococcal challenge was con-
ducted in 2012. Study design and outcomes have been previously
reported [9]. Briefly, 96 healthy volunteers aged 18–50 were vacci-
nated with either PCV-13 (PCV arm, n = 48) or Hepatitis A vaccine
(control arm, n = 48). 4–5 weeks post-vaccination, volunteers were
inoculated with 80,000 Colony-Forming Units (CFU) per nostril of
live 6B pneumococcus (BHN418, sequence type 138) [9]. Nasal
wash samples were taken and processed to obtain a nasal wash
supernatant and a nasal wash bacterial pellet as described previ-
ously [13], before and after pneumococcal inoculation (at days 2,
4, 14 and 21). Samples were stored at 80 C. This trial was
approved by The National Health Service Research and Ethics Com-
mittee (REC) (12/NW/0873 Liverpool) and was co-sponsored by the
Liverpool School of Tropical Medicine and the Royal Liverpool and
Broadgreen University Hospitals Trust. Informed consent was
obtained from all volunteers.
2.2. DNA extraction
300 ll of D2, D7 and D14 nasal wash bacterial pellets was cen-
trifuged for 7 min at 20,238g. Following centrifugation, 300 ll of
lysis buffer with protease, 100 ll of Zirconium beads (Stratech,
Ely, UK) and 300 ll of Phenol (Sigma-Aldrich, St Louis, MO, USA)
was added to the pellet and the sample was disrupted twice for
3 min in a tissue homogenizer (Bertin Technologies, Montigny le
Bretonneux, France) followed by 3 min on ice. The sample was cen-
trifuged for 10 min at 9391g, and the upper aqueous phase was
transferred to a tube pre-filled with 600 ll binding buffer and
10 ll magnetic beads. The samples were incubated at room tem-
perature for 30–120 min then washed twice with 200 ll of wash
buffers 1 and 2. Magnetic beads were dried at 55 C for 10 min,
eluted in 63 ll of elution buffer and stored at 20 C. Lysis buffer,
protease, binding buffer, magnetic beads, wash buffers 1 and 2, and
elution buffer are part of the Agowa mag Mini DNA isolation kit
(LGC Genomics, Berlin, Germany).
2.3. Multiplex qPCR
We developed a novel multiplex qPCR based on methods previ-
ously published, using partial amplification of lytA [11] and 6A/B
cpsA [14] genes. The sequences of the primers and probes used
are: lytA forward primer: 50-ACG-CAA-TCT-AGC-AGA-TGA-AGC-A-
30; lytA reverse primer 50-TCG-TGC-GTT-TTA-ATT-CCA-GCT-30; lytAprobe: 50-(FAM)-TGC-CGA-AAA-CGC-TTG-ATA-CAG-GGA-G-(BHQ-
1)-30; cpsA forward primer: 50-AAG-TTT-GCA-CTA-GAG-TAT-GGG-
AAG-GT-30; cpsA reverse primer: 50-ACA-TTA-TGT-CCA-TGT-CTT-C
GA-TAC-AAG-30; cpsA probe: 50-(HEX)- TGT-TCT-GCC-CTG-AGC-A
AC-TGG-(BHQ-1)-30. The reaction mixture of 25 ml contained
0.6 mM of each lytA primer, 0.3 mM of lytA probe, 0.4 mM of each
cpsA primer, 0.2 mM of cpsA probe, 12.5 mM of Taqman Gene
Expression Master Mix (Applied Biosystems, USA) and 2.5 ml of
extracted DNA. The qPCR reaction was run on a Mx3005P machine
(Agilent Technologies, Santa Clara, CA, USA) on the following pro-
gramme: 10 min at 95 C followed by 40 cycles of 15 s at 95 C
and 1 min at 60 C. DNA from BHN418 serotype 6B, extracted using
the QIAamp DNA mini kit (Qiagen, Hilden, Germany) and serially
diluted 1:10 from 4.14  106 copies in 2.5 ml, was used as a stan-
dard curve. A sample was considered positive if at least one dupli-
cate had a CT value less than 40. The 40 cycle cut-off correlates
well with classical culture data where it is known whether or not
viable serotype 6B pneumococcus has been isolated.
2.4. Statistical analysis
Risk Ratio, 95% confidence interval (CI) and p-value were calcu-
lated. Colonisation densities were determined from number of
gene copies per well and analysed in GraphPad Prism v5 (GraphPad
Inc.). Densities were log-transformed and means with standard
deviations were calculated. Unpaired t-tests were used to compare
densities in PCV and control arms.3. Results
3.1. Colonisation acquisition rates by molecular methods
Samples from 90 of the 98 volunteers enrolled in the EHPC PCV
study were available and included in these analyses. The re-
assessment of the PCV/EHPC trial samples using the developed
multiplex qPCR showed that all volunteers reported as
colonisation-positive (acquired the inoculated bacterium) by clas-
sical culture were also found to be colonised with pneumococcus
by molecular methods. However, the number of colonisation-
positive volunteers increased in both PCV and control arms when
using molecular methods. Positivity at any day for both lytA and
cpsA was found in 22/45 (49%) volunteers in the PCV arm and
31/45 (69%) volunteers in the control arm (Table 1). The risk ratio
by classical culture was 0.17 (95% CI, 0.07–0.46; P = 0.0005) and by
molecular methods was 0.71 (95% CI, 0.50–1.01; P = 0.06). PCV
conferred 83% protection against experimental pneumococcal
colonisation by classical culture, and 29% protection by molecular
methods.
When assessing the breakdown of colonisation-positive volun-
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Fig. 1. Colonisation densities by vaccination group, detection method and study time-point. Values shown are the log10 mean copies/mL ± SD. Classical culture data has been
previously reported [9].
Table 2
Comparison of colonisation density of colonised volunteers by detection method,
study day and study arm.
Classical Culture
Log10 CFU/ml




PCV Control PCV Control
D2 1.73 ± 0.02 2.47 ± 1.39 1.22 ± 0.80 2.21 ± 1.29
D7 0.85 ± 0.67 2.70 ± 1.64 1.13 ± 0.52 2.44 ± 1.56
D14 1.42 2.28 ± 1.58 1.86 ± 0.16 2.98 ± 0.93
Definition of abbreviations: PCV = pneumococcal conjugate vaccine; CFU = colony
forming units; SD = standard deviation; NW = nasal wash.
E.L. German et al. / Vaccine 37 (2019) 3953–3956 3955volunteers by lytA/cpsA multiplex qPCR was similar between D2
and D7 regardless of study arm (Table 1).
3.2. Colonisation densities by molecular methods
Colonisation densities were significantly lower in volunteers
vaccinated with PCV compared to the control arm by both classical
culture (P = 0.03) and molecular methods (P < 0.0001) (Fig. 1,
Table 2).
There was a significant correlation between densities calculated
by classical culture and by lytA/cpsA qPCR for volunteers in both
PCV (P < 0.0001; r2 = 0.54) and control arms (P < 0.0001;
r2 = 0.85). 91% of samples positive by lytA/cpsA qPCR but not by
classical culture had densities < 30 DNA copies/ml. There is no sig-
nificant difference between mean densities calculated by classical
or molecular methods, either in the PCV or in the control arm
(Table 2). By either detection method, densities in the PCV arm
were significantly lower (P = 0.0010 by classical culture and
P < 0.0001 for molecular methods) than in the control arm.4. Discussion
In this study we re-assessed the experimental colonisation sta-
tus of all volunteers from our PCV/EHPC trial using a multiplex
qPCR. The number of volunteers that became colonised after exper-
imental pneumococcal inoculation by molecular methods was
higher than the number previously reported by classical culture
[9]. This increase in number is more pronounced in the PCV arm
(23 vs 4 volunteers) than in the control arm (31 vs 23 volunteers),which translates into increased risk ratios, and therefore a decrease
in the calculated protective efficacy of PCV against pneumococcal
colonisation from 83% to 29%.
Molecular methods such as qPCR can detect DNA from dead
bacteria. However, it is unlikely that this phenomenon had a major
contribution to our findings. If this method were detecting remains
of the pneumococcal inoculum administered on Day 0, we would
expect to see higher colonisation rates at D2 than D7. However,
the colonisation rates on both days are comparable.
The cpsA gene sequence used in our multiplex qPCR is common
to both serotypes 6A and 6B. However, epidemiological studies
have reported that the incidence of pneumococcal serotype 6A is
very low in the UK in the post-PCV era; this was confirmed by
screening 795 volunteers for the EHPC studies in Liverpool which
found only one volunteer carrying a serotype 6A [15]. Pneumococ-
cal capsular genes have recently been discovered in other strepto-
cocci [16,17], raising the possibility that the additional gene copies
detected by qPCR derive from non-pneumococcal streptococci.
Nevertheless, in the context of the EHPC model, screening samples
are taken before inoculation, carriage is assessed very soon post-
inoculation and volunteers have limited contact with children.
The most likely explanation for the detection of lytA and cpsA genes
in our multiplex qPCR is carriage of the experimental 6B pneumo-
coccus used.
Both classical culture and molecular detection methods demon-
strate a lower colonisation density in volunteers vaccinated with
PCV. The additional colonised volunteers detected in both arms
by molecular methods are mostly colonised at a low density. It
has been suggested that colonisation density plays an underesti-
mated but pivotal role in the development of pneumococcal dis-
ease and in transmission dynamics [18,19]. Our results further
support the hypothesis that colonisation density is a determining
factor for the clinical outcome and spread of S. pneumoniae. It is
plausible that a novel vaccine that controlled pneumococcal
colonisation density independently of any effect on pneumococcal
acquisition would be effective in reducing pneumococcal disease.
Measures of colonisation density, by both classical culture and
molecular methods, should therefore be accounted for in the
design of vaccine efficacy trials, as was demonstrated recently in
a Phase 2 trial of a novel pneumococcal vaccine [20].
Findings from previous epidemiological studies have proved
inconclusive regarding the impact of PCVs on pneumococcal
colonisation density [5–8]. The advantage of the EHPC model is
3956 E.L. German et al. / Vaccine 37 (2019) 3953–3956the ability to study colonisation dynamics in a controlled manner,
clarifying causality and eliminating the effect of many confounding
factors. Its main disadvantage is the ethical imperative to use adult
volunteers rather than children. It is possible that the effect of PCV
on colonisation density differs between adults and children, and
our findings will need to be validated in younger cohorts.
5. Conclusions
Using molecular methods, we have shown that PCV conferred
29% protection against experimental colonisation acquisition. This
may indicate that the main protective mechanism of this vaccine is
mediated by reduction of colonisation density, leading to a
decreased risk of disease to vaccinated individuals as well as trans-
mission resulting in the observed herd effects in vaccinated
populations.
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